GFS Advisors LLC Increases Position in Bristol-Myers Squibb Co (BMY)

GFS Advisors LLC lifted its position in Bristol-Myers Squibb Co (NYSE:BMY) by 59.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,240 shares of the biopharmaceutical company’s stock after purchasing an additional 2,330 shares during the period. GFS Advisors LLC’s holdings in Bristol-Myers Squibb were worth $324,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Bristol-Myers Squibb by 1.0% in the third quarter. Vanguard Group Inc. now owns 128,376,159 shares of the biopharmaceutical company’s stock worth $7,969,593,000 after buying an additional 1,229,553 shares in the last quarter. Vanguard Group Inc raised its stake in Bristol-Myers Squibb by 1.0% in the third quarter. Vanguard Group Inc now owns 128,376,159 shares of the biopharmaceutical company’s stock worth $7,969,593,000 after buying an additional 1,229,553 shares in the last quarter. BlackRock Inc. raised its stake in Bristol-Myers Squibb by 0.9% in the fourth quarter. BlackRock Inc. now owns 115,573,078 shares of the biopharmaceutical company’s stock worth $6,007,489,000 after buying an additional 999,193 shares in the last quarter. Dodge & Cox raised its stake in Bristol-Myers Squibb by 0.8% in the third quarter. Dodge & Cox now owns 32,969,186 shares of the biopharmaceutical company’s stock worth $2,046,727,000 after buying an additional 264,100 shares in the last quarter. Finally, Primecap Management Co. CA raised its stake in Bristol-Myers Squibb by 4.8% in the third quarter. Primecap Management Co. CA now owns 18,906,694 shares of the biopharmaceutical company’s stock worth $1,173,728,000 after buying an additional 862,900 shares in the last quarter. Hedge funds and other institutional investors own 73.14% of the company’s stock.

A number of brokerages recently commented on BMY. ValuEngine raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Friday, December 7th. Bank of America reduced their price objective on shares of Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating for the company in a research note on Tuesday, February 19th. William Blair reissued an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Tuesday, November 27th. Edward Jones downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Friday, January 4th. Finally, Credit Suisse Group reissued a “hold” rating and issued a $59.00 price objective on shares of Bristol-Myers Squibb in a research note on Thursday, December 13th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $59.13.

Shares of BMY stock opened at $48.16 on Friday. The firm has a market cap of $79.87 billion, a PE ratio of 12.10, a price-to-earnings-growth ratio of 2.50 and a beta of 0.81. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.50 and a current ratio of 1.61. Bristol-Myers Squibb Co has a 12-month low of $44.30 and a 12-month high of $64.05.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.09. The business had revenue of $5.97 billion for the quarter, compared to the consensus estimate of $5.95 billion. Bristol-Myers Squibb had a return on equity of 48.99% and a net margin of 21.95%. The business’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.68 earnings per share. On average, analysts predict that Bristol-Myers Squibb Co will post 4.15 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.41%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is presently 41.21%.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2019/03/23/gfs-advisors-llc-increases-position-in-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Further Reading: Retained Earnings

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.